Operation Warp Speed
The Military Health System (MHS) is fully supporting the Department of Defense’s (DoD’s) whole-of-government partnership for Operation Warp Speed (OWS). On May 15, 2020, the White House announced OWS to accelerate the development, production and distribution of COVID-19 vaccines, therapeutics and diagnostics to the American public, with a goal to produce and deliver 300 million doses of a safe and effective vaccine by January 2021.
Part of the DoD and MHS contribution to OWS includes providing study sites at military medical treatment facilities (MTFs) and clinical trial centers for the conduct of Phase III clinical trials of vaccines.
Five MTFs in three health care markets are participating in AstraZeneca's Phase III trials:
Interested in Participating?
Participation is completely voluntary. If interested in participating in AstraZeneca’s Phase III trials:
You’ll be contacted by the local study site if you’re selected to participate.
Frequently Asked Questions
Questions and Answers about Operation Warp Speed.
Q1:
Will other DoD locations be added to this trial?
A:
No additional DoD locations will be added for the AstraZeneca trials. Additional MTFs are being considered for other trials for different COVID-19 vaccine candidates. Multiple other large Phase III vaccine trials are anticipated to evaluate different vaccines in development. These other trials will start later in the fall and winter.
Q2:
How long will these trials last?
A:
Each trial lasts two years. Interim analyses will be conducted at scheduled time-points during the first year of the trial to evaluate safety of the vaccine and how well it protects people from getting sick from SARS-CoV-2 (efficacy).
Q3:
What happens if we don’t reach the volunteer goals at a location?
A:
Each trial has an overall target enrollment of 30,000 participants. The military sites have a goal to enroll 1,000 study volunteers in each market area (for a total target of 3,000 volunteers). There will be more than 80 sites across the country participating in the trial and the trial will have “competitive enrollment.” This means that sites participating in the trial will continue to enroll study volunteers until the total study enrollment target of 30,000 is met, and will stop as soon as that target enrollment for the study is met.
Q4:
Will military members be directed to “volunteer” for the trials?
A:
Absolutely not. Any adult MHS beneficiary (active duty, retired, or family member) interested in participating in the study will be informed about the study and would need to provide voluntary written informed consent in order to be screened and considered for participation.
- Active duty members who are considered vulnerable from an ethical and regulatory standpoint (including new recruits and trainees) are excluded from the study and won’t be able to participate.
- Active duty military members who don’t fall into those categories may be able to participate in the study.
- Service members should consult with the study coordinator if they expect a permanent change of duty station or deployment within 12 months of beginning participation.
You also may be interested in...
Video
11/3/2020
This video provides a detailed overview of the processes that have been implemented to accelerate the pace of the COVID-19 vaccine and antibody studies, and what is being done to assure safety.
Recommended Content:
Coronavirus | COVID-19 Vaccine Efforts
Video
11/3/2020
This video discusses why enrolling diverse participants in COVID-19 studies is critical for ensuring that, when we find a vaccine, we have enough data from populations who are most affected by COVID-19 to determine vaccine safety and efficacy.
Recommended Content:
COVID-19 Vaccine Efforts | Coronavirus
Showing results 1 - 5
Page 1 of 1